Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Apple Turns 50: From Garage Startup to AI Crossroads 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Bank of America's $72.5M Epstein Settlement: What You Need to Know 
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 
 & Lead Plaintiff Deadline: September 5, 2017 - EconoTimes)
NEW YORK, July 13, 2017 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Ocular Therapeutix, Inc. (“Ocular” or the “Company”) (NASDAQ:OCUL) and certain of its officers, on behalf of shareholders who purchased Ocular securities between May 5, 2017 and July 6, 2017, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: http://www.bgandg.com/ocul.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.
The complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Ocular Therapeutix’s management has been misleading investors about DEXTENZA manufacturing issues, including that more than 50% of lots manufactured by Ocular Therapeutix contain bad product; (2) such manufacturing issues could imperil the approval of DEXTENZA by the FDA; and (3) consequently, defendants’ public statements were materially false and misleading at all relevant times.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/ocul or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Ocular you have until September 5, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | [email protected]
